

# [PDF] Recent Advances in the Treatment of Opioid Use Disorders


https://crimsonpublishers.com/tnn/pdf/TNN.000572.pdf

Recently three novel long-acting buprenorphine depot or implant formulations have been studieD and in part approved for treatment of opioid use disorders: for subcutaneous weekly and monthly application the depot formulations CAM 2038 [Buvidal®], the monthly

#### Recent Advances in the Treatment of Opioid Use Disorder ...

https://www.researchgate.net/publication/349989769...

Apr 01, 2021 · Recent Findings Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment





# Recent Advances in the Treatment of Opioid Use Disorder https://link.springer.com/article/10.1007/s11916-021-00941-8 •

Mar 11, 2021 - Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment (MAT) include office-based methadone maintenance, implantable and monthly injectable buprenorphine, and an extended-release injectable naltrexone.

Author: Sumanth Kuppalli, Raghav Seth, Vwai... Publish Year: 2021

(PDF) Advances in the treatment of opioid use disorders https://www.researchgate.net/publication/313015254...







#### Recent Advances in the treatment of opioid use disorders-focus or







ALL

IMAGES

VIDEOS

11,300 Results

Any time ▼

## [PDF] Recent Advances in the Treatment of Opioid Use Disorders

#### https://crimsonpublishers.com/tnn/pdf/TNN.000572.pdf

Recently three novel long-acting buprenorphine depot or implant formulations have been studieD and in part approved for treatment of opioid use disorders: for subcutaneous weekly and monthly application the depot formulations CAM 2038 [Buvidal®], the monthly

### Recent Advances in the Treatment of Opioid Use Disorder ...

https://link.springer.com/article/10.1007/s11916-021-00941-8 -

Mar 11, 2021 - Transdermal buprenorphine (Butrans™) is available in doses between 5 and 20 mcg/h that is used for chronic pain requiring around-the-clock opioid therapy and may be used for OUD treatment in the future. A long-acting buprenorphine implant called Probuphine was approved by the US Food and Drug Administration in 2016 and delivers a steady state of medication over a 6-month period [30•].

Author: Sumanth Kuppalli, Raghav Seth, Vwai... Publish Year: 2021

## (PDF) Advances in the treatment of opioid use disorders

https://www.researchgate.net/publication/313015254...

Jan 27, 2017 · PDF | The development of medications for treating persons with opioid use disorders has expanded the number of evidence-based treatment options,... | ...

# Novel Formulations of Buprenorphine for Treatment of ...

https://focus.psychiatryonline.org/doi/full/10.1176/appi.focus.20180043

Buprenorphine For Treatmen...

Benefits and Issues with Oral...

Rationale | >



The Drug Addiction Treatment Act of 2000 extended medical treatment of OUD further into the community by allowing patients to be prescribed sublingual buprenorphine by physicians in their offices, as long as the office-based prescribers had received sufficient training (8 hours) to obtain a waiver from the Drug Enforcement Administration (DEA) to legally prescribe buprenorphine for addiction treatment. Sublingual buprenorphine is an inverse mu opioid receptor agonist and a Schedule III narcotic for the tr...

#### See more on focus.psychiatryonline.org

Cited by: 2 Author: Richard N Rosenthal

Publish Year: 2019